Epilepsy: Global Forecast & Market Analysis to 2035 - UCB Will Continue to Dominate the Epilepsy Market with Key Drugs Keppra & Vimpat - ResearchAndMarkets.com

The "Epilepsy
Forecast and Market Analysis to 2035" report has been added to ResearchAndMarkets.com's
offering.

Market Snapshot

• Label expansions will drive uptake of newer brands, sustaining the
  epilepsy market by countering widespread genericization.
• Levetiracetam, valproate formulations, lamotrigine, and carbamazepine
  constitute the mainstay of epilepsy treatment.
• Although approximately 70% of epilepsy patients respond to treatment,
  the number of prevalent cases of active epilepsy remains high.
• UCB will continue to dominate the epilepsy market with key drugs
  Keppra and Vimpat.
• With positive Phase III data in LGS, Epidiolex is proving to be the
  therapy of choice for refractory childhood epilepsy.

Key Topics Covered

FORECAST: EPILEPSY

Overview

Executive Summary

Market Overview And Trends

Market Definition And Methodology

Aptiom/Zebinix (Eslicarbazepine)

Banzel/Inovelon (Rufinamide)

Briviact (Brivaracetam)

Epidiolex (Cannabidiol)

Fycompa (Perampanel)

Keppra/Keppra Xr (Levetiracetam)

Lamictal/Lamictal Xr (Lamotrigine)

Lyrica (Pregabalin)

Onfi (Clobazam)

Vimpat (Lacosamide)

Primary Research Methodology

TREATMENT: EPILEPSY

Overview

Executive Summary

Primary Research Methodology

Disease Definition And Diagnosis

Patient Segmentation

Current Treatment Options

Treatment Dynamics

Unmet Needs In Epilepsy

EPIDEMIOLOGY: EPILEPSY

Overview

Disease Background

Methodology

Forecast

Bibliography

Appendix: Additional Sources

MARKETED DRUGS: EPILEPSY

Overview

Executive Summary

Product Overview

Product Profile: Aptiom

Product Profile: Banzel

Product Profile: Briviact

Product Profile: Fycompa

Product Profile: Keppra And Keppra Xr

Product Profile: Lamictal And Lamictal Xr

Product Profile: Lyrica

Product Profile: Onfi

Product Profile: Vimpat

PIPELINE: EPILEPSY

Overview

Executive Summary

Clinical Pipeline Overview

Latest Analyst Opinion

Additional Pharma Intelligence Pipeline Resources

Product Profile (Late Stage): Epidiolex

Product Profile (Late Stage): Ganaxolone

For more information about this report visit https://www.researchandmarkets.com/r/kxsgan

View source version on businesswire.com: https://www.businesswire.com/news/home/20190618005988/en/